Recent breakthroughs show that China is emerging as a world leader in stem cell research and development, said Ms Cindy Morrissey, president & CEO, Emerging Healthcare Solutions, a company that invests and participates in the profits of emerging breakthrough medical technologies. In recent years, the Asian superpower has encouraged the development of innovative new stem cell therapies, with government incentives and favorable regulatory practices. “The true frontiers of stem cell research and treatment are being explored today in China,” Ms Morrissey said. “The government has fostered an environment there that is conducive to testing and perfecting radical new treatments that are already changing the face of medicine. We view that environment as crucial to EHSI’s stem-cell plans.” Recently, EHSI affiliate Celulas Genetica purchased a license to develop and market the revolutionary Rutherford Procedure, a groundbreaking organ regeneration treatment intended to utilize proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells. Celulas Genetica licensed the procedure from a Chinese firm, BBFITCL, and views the emerging Asian superpower as the ideal locale to test and develop the Rutherford Procedure as a potential treatment for liver disease. EHSI is negotiating to obtain a license for a rotating-wall bioreactor originally developed by NASA with the ability to multiply adult stem cells. The company hopes that stem cells grown inside the bioreactor can be used to help regenerate damaged tissue into healthy, functional organs.